- |||||||||| octreotide acetate / Generic mfg.
Journal: A Long-Term Follow-Up of 2 Cases of Subclinical Acromegaly. (Pubmed Central) - Jul 18, 2025 She was started on long-acting octreotide due to reluctance for transsphenoidal surgery...These cases highlight the importance of screening all patients with pituitary lesions using an IGF-1 level regardless of presence of classical symptoms of acromegaly. On long-term follow-up, subclinical acromegaly after treatment has a relatively benign course without development of associated comorbidities, although additional studies involving large number of patients are needed.
- |||||||||| Somavert (pegvisomant) / Pfizer, Signifor (pasireotide) / Recordati
Review, Journal: Impact of Medical Therapies on Cardiovascular Risk Factors in Acromegaly. (Pubmed Central) - Jul 17, 2025 The long-acting somatostatin receptor ligand pasireotide, on the other hand, was associated with an increase in these glucose parameters...A significant reduction in lipid parameters was also observed in patients treated with somatostatin receptor ligands. However, the impact of these agents on blood pressure control was confounded by concurrent antihypertensive therapies.
- |||||||||| cabergoline / Generic mfg., Somavert (pegvisomant) / Pfizer, Signifor (pasireotide) / Recordati
Journal, HEOR: Cost-utility analysis of second line acromegaly treatment in France. (Pubmed Central) - Jul 12, 2025 This is an important factor for patients, given that acromegaly treatments are chronic and usually lifelong. This study is an additional tool for treatment choice including both a clinical and economic perspective.
- |||||||||| Airway Management in a Non-reassuring Airway in Acromegaly (212B, Meeting Level) - Jul 12, 2025 - Abstract #ASA2025ASA_35;
This case explores preoperative considerations, perioperative management, and anticipated postoperative complications, which were further complicated by an acromegalic patient. There is no abstract associated with this presentation.
- |||||||||| PAS-403 / Pascal Biosci
ST403. Airway Management in Complex Neuroanesthesia Scenarios - Decoding the Decision Making Process (1 PS, 1 CME) (212B, Meeting Level) - Jul 12, 2025 - Abstract #ASA2025ASA_31; They will gain knowledge of various airway devices and understand the appropriate use of each, ultimately leading to improved patient outcomes. SessionLearningObjective1: Interpret the data on preoperative airway evaluation in a neurosurgical patient with a challenging airway such as traumatic brain/spine injury and acromegaly.SessionLearningObjective2: Formulate a plan of airway management in a desaturating patient undergoing awake craniotomy with the head fixed in pins or a stereotaxic frame.SessionLearningObjective3: Construct a plan to manage a patient coming back to the operating room with an expanding neck hematoma after a carotid endarterectomy.
- |||||||||| Journal: Medical Treatment of Acromegaly: Navigating the Present, Shaping the Future. (Pubmed Central) - Jul 11, 2025
In addition, shifting from the current trial-and-error approach to a more precise treatment strategy guided by biomarkers predictive of the response to different medical therapies will optimize and improve patient outcomes. In this review, current treatments as well as new drugs in different phases of development are detailed, and the role of precision medicine in the treatment of acromegaly is discussed.
- |||||||||| Journal: Exploring the Symptoms and Treatment of a Pituitary Macroadenoma: A Case Report. (Pubmed Central) - Jul 10, 2025
This case emphasizes the importance of considering macroadenomas in differential diagnosis when encountering unusual patient presentations with a complex medical history. Therefore, early diagnosis and individualized management are crucial for achieving optimal outcomes.
- |||||||||| Journal, HEOR: Clinical and economic burden among older adults with acromegaly in the United States. (Pubmed Central) - Jul 8, 2025
The majority of beneficiaries with acromegaly (69.6%) did not have evidence of acromegaly treatment. Medicare beneficiaries with acromegaly have substantial HCRU and costs compared with controls without acromegaly; this indicates a high burden of illness which may be lessened by new and effective therapeutic options for those with acromegaly.
- |||||||||| Journal, HEOR: Healthcare utilization and costs among patients with acromegaly in the United States. (Pubmed Central) - Jul 8, 2025
Patients with acromegaly had higher HCRU and costs than matched patients without acromegaly, and the presence of acromegaly with high-risk comorbidities was associated with a substantial HCRU and cost burden. This high burden of illness may be alleviated with better disease control.
- |||||||||| Journal: Thoracic Back Pain Leading to an Acromegaly Diagnosis: A Case Report. (Pubmed Central) - Jul 8, 2025
Follow-up imaging identified a growth hormone (GH)-secreting pituitary macroadenoma with local invasion. To the best of our knowledge, this is the first time the finding of DISH has hinted at the possibility of acromegaly, and may illustrate
- |||||||||| Somavert (pegvisomant) / Pfizer, Signifor (pasireotide) / Recordati, Signifor LAR (pasireotide long acting release) / Recordati
Retrospective data, Review, Journal: Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis. (Pubmed Central) - Jul 7, 2025 In this large meta-analysis, PasiLAR was associated with increased HDL-C, FPG, HbA1c, and frequency of DM in patients with acromegaly. There was no effect on triglycerides, total cholesterol, and LDL-C.
- |||||||||| Resistant And Sensitive Gh Pituitary Neuroendocrine Tumors Resolved By Spatial Transcriptomics (ENDOExpo - Poster Area; Board No. MON-062) - Jul 3, 2025 - Abstract #ENDO2025ENDO_3949;
Similar findings were observed in the second group. We then performed a cell cycle analysis, showing that most spots/clusters are in G0/G1 cell cycle phase with very low number of spots in S, G2/M and early G1, this results in disregard of the SA-response status.We previously showed that sphingolipid and MAPK signaling pathways are altered in aggressive and recurrent PitNET and could represent an attractive molecular target.
- |||||||||| Somavert (pegvisomant) / Pfizer
Age-related Immunosenescence In Bgh Mice: Insights From The Spleen And Bone Marrow (ENDOExpo - Poster Area; Board No. SUN-091) - Jul 3, 2025 - Abstract #ENDO2025ENDO_3747; In conclusion, bGH mice showed shifts in the lymphocyte population that are characteristic of premature aging, suggesting that excess GH action accelerates immunosenescence. These findings suggest the potential therapeutic use of the drug that decreases GH action, such as the GH antagonist, Pegvisomant (FDA-approved drug to treat acromegaly), to mitigate immune aging and improve various aspects of healthspan.
- |||||||||| cucurbitacin I (JSI-124) / H. Lee Moffitt Cancer Center and Research Institute, University of South Florida
Screening For Therapeutic Targets To Suppress GH Production And Proliferation In AIP Mutant GH-producing Cells (ENDOExpo - Poster Area; Board No. SAT-095) - Jul 3, 2025 - Abstract #ENDO2025ENDO_3589; Cucurbitacin I downregulated POU1F1 expression at both mRNA and protein levels, suggesting that GH1 suppression is mediated through POU1F1 downregulation. These findings indicate the JAK2-STAT3 pathway and actin polymerization as potential therapeutic targets for drug-resistant, AIP-mutant pituitary tumors.
- |||||||||| desmopressin / Generic mfg.
Acromegaly In Transitions: Overlap Of Endocrine And Gender Health (ENDOExpo - Poster Area; Board No. SAT-089) - Jul 3, 2025 - Abstract #ENDO2025ENDO_3587; A prior case described a female-to-male transgender patient whose features of acromegaly were initially misattributed to gender-affirming hormonal therapy1. This case underscores the importance of maintaining a broad differential diagnosis when evaluating new somatic changes in transgender individuals.
- |||||||||| Chair (Yerba Buena, Salon 10-14; Marriott Marquis) - Jul 3, 2025 - Abstract #ENDO2025ENDO_3566;
While CGRP expression was not significantly associated with chronic headache, patients with CGRP-positive tumors exhibited a higher frequency of persistent headache, suggesting a potential link between CGRP and symptom persistence in acromegaly. This activity is supported by an independent educational grant from Crinetics Pharmaceuticals.
- |||||||||| Faculty (Yerba Buena, Salon 10-14; Marriott Marquis) - Jul 3, 2025 - Abstract #ENDO2025ENDO_3558;
This activity is supported by an independent educational grant from Crinetics Pharmaceuticals. This activity is supported by an independent educational grant from Crinetics Pharmaceuticals.
- |||||||||| Faculty (Yerba Buena, Salon 10-14; Marriott Marquis) - Jul 3, 2025 - Abstract #ENDO2025ENDO_3557;
This activity is supported by an independent educational grant from Crinetics Pharmaceuticals. This activity is supported by an independent educational grant from Crinetics Pharmaceuticals.
- |||||||||| Structural knee MRI changes in patients with acromegaly. (Discovery Hall, Hall 4B (Seattle Convention Center)) - Jul 1, 2025 - Abstract #ASBMR2025ASBMR_914;
Hoffa's fat pad edema appears to be a specific change in the knee joints of patients with acromegaly, regardless of disease activity. These findings suggest that altered joint geometry, rather than degenerative pathology, may be the primary cause of knee pain in this population.
- |||||||||| Journal: Management of patients with acromegaly in clinical practice in the gulf countries: a Delphi consensus survey. (Pubmed Central) - Jun 27, 2025
The consensus reflects pragmatic adaptations to resource availability, such as endorsing watchful waiting in specific contexts. While acknowledging limitations such as potential expert bias, these consensus guidelines provide a framework for standardizing acromegaly care across the Gulf countries, with emphasis on surgical intervention as the cornerstone of treatment while recognizing the importance of adjunctive therapies.
- |||||||||| Journal, HEOR: Oral Health and Quality of Life in Acromegaly: A Questionnaire-Based Study. (Pubmed Central) - Jun 25, 2025
Oro-facial changes significantly affect quality of life in cases of acromegaly, yet dental professionals' involvement in diagnosis and management is limited. Greater awareness among and integration of dental professionals could support earlier detection and improve patient outcomes.
- |||||||||| Journal: Living with (Pubmed Central) - Jun 23, 2025
An increased awareness about endocrine diseases in the general population and health professionals may contribute to earlier diagnosis of pituitary adenomas. No abstract available
- |||||||||| dexamethasone / Generic mfg., cabergoline / Generic mfg.
Journal: Hypersomatotropism and Hypercortisolism Caused by a Plurihormonal Pituitary Adenoma in a Dog. (Pubmed Central) - Jun 17, 2025 An abnormal low-dose dexamethasone suppression test and increased circulating adrenocorticotropic (ACTH) concentration indicated pituitary-dependent hypercortisolism...Treatment with cabergoline initially decreased circulating IGF-1 and ACTH concentrations and urinary cortisol-to-creatinine ratio (UCCR), with a notable reduction in acromegalic physical features...On necropsy, double immunohistochemistry identified pituitary tumor cells with cytoplasmic co-expression of both growth hormone (GH) and ACTH, consistent with a monomorphic plurihormonal macroadenoma. This case shows that concurrent hypersomatotropism and hypercortisolism can occur in dogs caused by a plurihormonal pituitary adenoma.
|